9-Methyl-beta-carboline — Safety, Research, Risks & Legal Status

Not medical advice. 9-Methyl-beta-carboline is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	9-ME-BC, 9-methyl-beta-carboline, 9-methylbeta-carboline
Category	Research Chemical
mao_b_inhibitor	In vitro studies show MAO-B inhibition; human effects unknown
no_human_trials	Zero published human studies or clinical data
research_tool	Used only in academic neuroscience; no pharmaceutical development
US legal status	Not FDA-approved. Sold as a research chemical for in vitro and animal studies. Not approved for human use. No regulatory framework or scheduled status in most jurisdictions.

What is 9-Methyl-beta-carboline?

9-ME-BC is a synthetic beta-carboline alkaloid analog designed to interact with the dopamine system, potentially modulating monoamine oxidase (MAO) and other neural pathways. Its exact human pharmacology is unknown.

How it works

Theorized MAO-B inhibitor that may enhance dopaminergic and noradrenergic signaling via monoamine preservation. Proposed to cross the blood-brain barrier and modulate dopamine and norepinephrine levels.

Background & history

Synthetic research compound developed to explore beta-carboline chemistry and dopamine modulation. Used primarily in academic neuroscience research; never advanced to human trials or pharmaceutical development.

What the research says

Preclinical animal studies suggest potential dopamine-enhancing and neuroprotective effects. No published human clinical trials exist. In vitro studies show MAO-B inhibition. All evidence is from animal models and cell culture.

Reported effects

Animal studies suggest potential dopamine-enhancing effects
Preclinical research indicates possible neuroprotective properties
In vitro data suggest MAO-B inhibition, which may increase catecholamine levels
Theoretical potential for improving motivation and mood based on dopamine mechanisms, but no human evidence

Dosing & administration (informational)

No human dosing information available. Animal studies employ wide dose ranges not translatable to human safety or efficacy.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

NO human safety studies; all evidence is from animal and in vitro research
Unknown bioavailability, metabolism, and organ toxicity in humans
Quality of research-chemical suppliers is completely unverified
Contamination and synthesis impurities are significant risks
Using an untested experimental compound in humans carries unknown and potentially severe risks

Drug & supplement interactions

Unknown; no human pharmacokinetic data
Potential serotonin-syndrome risk if combined with serotonergic agents (MAO inhibition)
Theoretical interaction with dopaminergic medications unclear

Who should avoid it

Any human use (completely untested in people)
Co-use with SSRIs or serotonergic agents (MAO inhibition increases serotonin syndrome risk)
Assumption that animal doses extrapolate to humans (cannot be done safely)
Use in individuals with monoamine-sensitive conditions (bipolar disorder, hypertension)

How it is commonly combined

Stacking with serotonergic or other dopaminergic compounds is contraindicated due to unknown and potentially severe interactions.

Legal & regulatory. Not FDA-approved. Sold as a research chemical for in vitro and animal studies. Not approved for human use. No regulatory framework or scheduled status in most jurisdictions.

Quality & harm reduction

D
e
m
a
n
d
t
h
i
r
d
-
p
a
r
t
y
C
o
A
c
o
n
f
i
r
m
i
n
g
p
u
r
i
t
y
,
i
d
e
n
t
i
t
y
,
a
n
d
p
o
t
e
n
c
y
;
f
e
w
s
u
p
p
l
i
e
r
s
h
a
v
e
t
e
s
t
e
d
s
t
o
c
k
.
P
r
e
f
e
r
s
u
p
p
l
i
e
r
s
w
i
t
h
f
u
l
l
s
y
n
t
h
e
s
i
s
d
o
c
u
m
e
n
t
a
t
i
o
n
a
n
d
r
e
p
r
o
d
u
c
i
b
l
e
a
n
a
l
y
t
i
c
a
l
p
r
o
c
e
d
u
r
e
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is 9-ME-BC tested in humans?

No human clinical trials have been published. 9-ME-BC is used only in animal research and in vitro studies.

What does 9-ME-BC do?

Animal studies suggest dopamine enhancement and neuroprotection. The exact mechanism in humans is unknown.

Is 9-ME-BC safe?

Safety is completely unknown in humans. All evidence comes from animal models, and human pharmacokinetics and toxicity have not been studied.

Could 9-ME-BC increase dopamine?

Animal studies suggest potential dopamine enhancement via MAO-B inhibition, but human effects are completely unproven.

What makes 9-ME-BC risky?

Complete lack of human safety or efficacy data, unknown pharmacokinetics, and potential for serious interactions with serotonergic medications.

References & further reading

P
r
e
c
l
i
n
i
c
a
l
b
e
t
a
-
c
a
r
b
o
l
i
n
e
p
h
a
r
m
a
c
o
l
o
g
y
;
M
A
O
-
B
i
n
h
i
b
i
t
i
o
n
s
t
u
d
i
e
s
;
d
o
p
a
m
i
n
e
-
m
o
d
u
l
a
t
i
o
n
r
e
s
e
a
r
c
h
;
a
n
i
m
a
l
n
e
u
r
o
p
r
o
t
e
c
t
i
o
n
m
o
d
e
l
s
.